Stocks News

LAST PRICE
139.0200
TODAY'S CHANGE (%)
Trending Down-4.1700 (-2.9122%)

Bid / Lots
125.5000/ 1
Ask / Lots
139.5000/ 1
Open / Previous Close
143.5000 / 143.1900
Day Range
Low 138.1500
High 143.5400
52 Week Range
Low 89.0400
High 148.3699
Volume
653,668
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 16 hours ago by PR Newswire
  16 hours ago by PR Newswire
  Companies Mentioned: NBIX
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 16 hours ago by Dow Jones
  16 hours ago by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
  
  PR Newswire
  
  SAN DIEGO, May 8, 2024
May 7, 2024
- Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by PR Newswire
  4:15PM ET on Tuesday May 07, 2024 by PR Newswire
  Companies Mentioned: NBIX
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.
- Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by Dow Jones
  4:15PM ET on Tuesday May 07, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
  
  PR Newswire
  
  SAN DIEGO, May 7, 2024
  
  SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.
- Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024, from 8:30AM ET on Tuesday May 07, 2024 by PR Newswire
  8:30AM ET on Tuesday May 07, 2024 by PR Newswire
  Companies Mentioned: NBIX
  -- CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia
  -- Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort(R)/Efmody(R)) in Adrenal Insufficiency

Yesterday
- United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: UTHR
- Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: MEDP
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV, from 16 hours ago by PR Newswire
  16 hours ago by PR Newswire
  Companies Mentioned: BMRN
May 7, 2024
- United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing, from 5:00PM ET on Tuesday May 07, 2024 by MT Newswires
  5:00PM ET on Tuesday May 07, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 6, 2024
- Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires
  4:47PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: BMRN
- United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires
  4:43PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: UTHR
- United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires
  4:43PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 4, 2024
- New Data for BioMarin's VOXZOGO(R) (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting, from 4:00PM ET on Saturday May 04, 2024 by PR Newswire
  4:00PM ET on Saturday May 04, 2024 by PR Newswire
  Companies Mentioned: BMRN
May 3, 2024
- United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing, from 4:39PM ET on Friday May 03, 2024 by MT Newswires
  4:39PM ET on Friday May 03, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 4:13PM ET on Friday May 03, 2024 by MT Newswires
  4:13PM ET on Friday May 03, 2024 by MT Newswires
  Companies Mentioned: MEDP

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Yesterday

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 16 hours ago by PR Newswire

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 16 hours ago by Dow Jones

May 7, 2024

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by PR Newswire

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by Dow Jones

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024, from 8:30AM ET on Tuesday May 07, 2024 by PR Newswire

Peers Headlines

Yesterday

United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing, from 7 hours ago by MT Newswires

Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 8 hours ago by MT Newswires

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV, from 16 hours ago by PR Newswire

May 7, 2024

United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing, from 5:00PM ET on Tuesday May 07, 2024 by MT Newswires

May 6, 2024

Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires

May 4, 2024

New Data for BioMarin's VOXZOGO(R) (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting, from 4:00PM ET on Saturday May 04, 2024 by PR Newswire

May 3, 2024

United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing, from 4:39PM ET on Friday May 03, 2024 by MT Newswires

Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 4:13PM ET on Friday May 03, 2024 by MT Newswires